- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07876440
A Clinical Study of HH-1270 in Healthy Chinese Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HH-1270 Tablets in Healthy Chinese Participants
This study is a single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial to evaluate the safety and PK profile in healthy Chinese subjects.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
SAD consists of 6 prespecified dose levels. Participants are enrolled in cohorts according to the dose-escalation principle and randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of single-dose HH-1270. One dose cohort in the SAD phase will be selected for a food-effect exploration.
MAD consists of 4 prespecified dose levels. Each participant receives once-daily dosing under fasting conditions for 7 consecutive days and is randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of multiple-dose HH-1270.
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Xiyu Zhang
- Numéro de téléphone: 18701650516
- E-mail: zhangxiyu@hhhbio.com
Lieux d'étude
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chine, 100191
- Recrutement
- Peking University Third Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Healthy Chinese adults aged 18 to 55 years (inclusive), both male and female.
- Weight: male ≥50.0 kg, female ≥45.0 kg, and body mass index (BMI) 18.0 to 28.0 kg/m² (inclusive; BMI = weight/height²).
- Results of vital signs, physical examination, laboratory tests, and 12-lead electrocardiogram (ECG) at screening are normal or abnormal without clinical significance.
- Participants must agree to take adequate and effective contraceptive measures.
- Participants understand and comply with the study procedures, voluntarily participate, and sign the informed consent form (ICF).
Exclusion Criteria:
- Individuals with severe systemic diseases, infectious diseases, or mental disorders.
- Clinically significant electrocardiogram (ECG) abnormalities.
- History of clinically significant drug allergy or atopic allergic diseases.
- Comorbid conditions that may affect drug absorption, distribution, metabolism, excretion, and interpretation of safety data, or that may reduce compliance, including but not limited to any of the following.
- Positive results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody (TPAb).
- History of drug abuse or alcoholism within 12 months before screening, or evidence of alcohol abuse or excessive drinking confirmed by an alcohol breath test at screening.
- Frequent use of tobacco or nicotine products (e.g., patches, gum, etc.) or any other smoking products within 30 days before screening.
- Blood donation ≥400 mL within 3 months before screening.
- Participation in another interventional clinical trial within 3 months before screening.
- Use of any prescription medication within 4 weeks or 5 half-lives (whichever is longer) before screening.
- Use of over-the-counter drugs, health supplements, herbal medicines, or traditional Chinese medicines, or use of medications that affect drug metabolism, within 2 weeks before screening.
- Known or suspected history of allergy to any component of HH-1270 tablets or their excipients.
- Inability to accept standardized diet management at the study center.
- Participants who are breastfeeding or have a positive pregnancy test before the first dose.
- Participants deemed unsuitable for participation in the study by the investigator.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: HH-1270 group
SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days |
SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days |
|
Comparateur placebo: Placebo group
SAD groups will be received HH-1270 placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days |
SAD groups will be received placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Délai: up to 15/21 days in SAD/MAD
|
Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v6.0. |
up to 15/21 days in SAD/MAD
|
|
Clinically significant abnormalities
Délai: up to 14/21 days in SAD/MAD
|
Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v6.0. |
up to 14/21 days in SAD/MAD
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Area Under the Plasma Concentration Versus Time Curve (AUC)
Délai: up to 8/14 days in SAD/MAD
|
AUC of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Maximum Plasma Concentration (Cmax)
Délai: up to 8/14 days in SAD/MAD
|
Cmax of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Time to Reach Maximum Plasma Concentration (Tmax)
Délai: up to 8/14 days in SAD/MAD
|
Tmax of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Apparent Terminal Elimination Half-life (T1/2)
Délai: up to 8/14 days in SAD/MAD
|
T1/2 of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Apparent Plasma Clearance (CL/F)
Délai: up to 8/14 days in SAD/MAD
|
CL/F of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Apparent volume of distribution(Vd/F)
Délai: up to 8/14 days in SAD/MAD
|
Vd/F of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
To evaluate the TBA level
Délai: up to 15/21 days in SAD/MAD
|
TBA level for each collection point |
up to 15/21 days in SAD/MAD
|
|
To evaluate the CP-1 level
Délai: up to 15/21 days in SAD/MAD
|
CP-1 level for each collection point |
up to 15/21 days in SAD/MAD
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
To evaluate QTc change
Délai: up to 8 days in SAD
|
QTc values in each collection point |
up to 8 days in SAD
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- HH1270-101
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .